Evidence map›Paper›PMID 33839992›Full record

ArticleClinical rheumatology2021

Metabolic syndrome and adipokine levels in systemic lupus erythematosus and systemic sclerosis.

Antonietta Gigante, Francesco Iannazzo, Luca Navarini, Maria Chiara Sgariglia, Domenico Paolo Emanuele Margiotta, Valentina Vaiarello, Federica Foti, Antonella Afeltra, Rosario Cianci, Edoardo Rosato

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical rheumatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Observational
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Antonietta Gigante *Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
Francesco Iannazzo *Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
Luca NavariniUnit of Allergology, Clinical Immunology and Rheumatology, Department of Medicine, Campus Bio-Medico University, Rome, Italy.
Maria Chiara SgarigliaDepartment of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
Domenico Paolo Emanuele MargiottaUnit of Allergology, Clinical Immunology and Rheumatology, Department of Medicine, Campus Bio-Medico University, Rome, Italy.
Valentina VaiarelloDepartment of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
Federica FotiDepartment of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
Antonella AfeltraUnit of Allergology, Clinical Immunology and Rheumatology, Department of Medicine, Campus Bio-Medico University, Rome, Italy.
Rosario CianciDepartment of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
Edoardo RosatoDepartment of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy. edoardo.rosato@uniroma1.it.ORCID http://orcid.org/0000-0002-7417-8093
Sapienza University of Rome · ITUniversità Campus Bio-Medico · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAims of study were to evaluate the prevalence of metabolic syndrome (MetS) in systemic lupus erythematosus (SLE) and systemic sclerosis (SSc) patients and to evaluate serum level of adipokines in SLE and SSc patients with and without MetS.

methodsFifty SLE patients and 85 SSc patients were enrolled. The diagnosis of MetS was made according to the criteria of the National Cholesterol Education Program (NCEP) Adult Treatment Panel III. Clinical assessment and serum levels of adiponectin and resistin were evaluate in SLE and SSc patients.

resultsPrevalence of MetS was significantly (p<0.0001) higher in SLE patients than SSc patients (36% vs 10.6%). Median values of resistin were significantly (p<0.001) higher in SLE patients with MetS than SLE patients without MetS [4.01 ng/mL (2.7-4.5) vs 1.92 ng/mL (1.2-3)]. Median values of adiponectin were significantly (p<0.05) lower in SLE patients with MetS than SLE patients without MetS [5.64 ng/mL (4.96-8) vs 8.38 ng/mL (6.54-11.01)]. Systemic Lupus Erythematosus Activity Index [8 (6-12) vs 10 (6-13), p<0.01] and Systemic Damage Index [2 (1-3) vs 2 (0-3), p<0.001] were significantly higher in MetS patients than in patients without MetS. In SSc, the median value of disease severity scale was significantly higher (p<0.05) in MetS patients than in patients without MetS [7 (5-7) vs 5 (3-6)].

conclusionPrevalence of MetS is higher in SLE patients. In SLE patients, MetS showed an association with adipokine levels and inflammation/activity disease scores. In SSc patients, MetS was associated with severity of disease. Key Points • Prevalence of metabolic syndrome is higher in SLE patients than SSc patients. • Resistin is higher in SLE patients with metabolic syndrome. • Adineponectin is lower in SLE patients with metabolic syndrome. • Disease severity scale is higher in SSc patients with metabolic syndrome.

Indexed as

Lupus Erythematosus, SystemicMetabolic SyndromeScleroderma, SystemicAdipokinesAdultHumansResistinAdipokinesResistinAdipokinesAdiponectinMetabolic syndromeResistinSystemic lupus erythematosusSystemic sclerosis

Identifiers

PMID33839992
PMCPMC8463337
OpenAlexW3155571550

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.